NVO Novo Nordisk A/S

NVO — Model Update | Post Q1 2026

Novo Nordisk A/S (NYSE: NVO) | 2026-05-26

Update Trigger & Summary

Novo Nordisk reported Q1 2026 on 2026-05-06. Mixed print masked a critical thesis-confirming datapoint: Wegovy oral pill (US launch Jan'26) generated DKK 2.26B in Q1 — nearly 2x consensus of DKK 1.16B — with 1.3M scripts and ~80% of users being GLP-1 treatment-naïve. This validates pipeline optionality at the expense of injectable cannibalization. Headline revenue DKK 70.1B (-10% reported / -4% FX-neutral) was a modest miss; gross margin compressed 290bp YoY to 80.6% on US pricing pressure. Reported operating margin 47% was inflated by a DKK 4.2B 340B provision reversal (underlying ~44%). FY26 guidance was raised by 1pp in parallel (sales -4% to -12% FX-neutral, prior -5% to -13%); stock closed +2.3% in Copenhagen (+6.7% intraday). We cut FY26E revenue -13% to align with guidance midpoint, trim EBITDA margin -350bp to 46%, and cut EPS -25.6%; partial FY27E recovery on Wegovy pill ramp + MASH/amycretin launches. TP $61.50 → $60.00 (-2.4%) — short-term EPS cuts offset by Wegovy pill validation lifting terminal value. MAINTAIN BUY; conviction unchanged at 4. Stock has recovered +11% since initiation ($40.46 → $44.96); upside to TP compressed to +33% but risk/reward remains attractive given pipeline density (3 Phase 3 readouts in next 12 months).

Q1 2026 Actuals vs. Prior Expectations (figures in DKK unless noted)

Wegovy Oral Pill — Launch KPIs (US, since Jan 2026)

Forward Estimate Revisions (DKK Billions unless noted)

FY 2026 Guidance Update (FX-Neutral)

Key Assumption Changes

• Revenue growth FY26E: +6.0% → -7.8% — Q1 -4% FX-neutral; aligns with guidance midpoint -8%; Ozempic US pricing -10/-15% + Mounjaro share gain in obesity.
• Gross margin FY26E: 83.5% → 80.5% — Q1 printed 80.6% on lower realized US prices, one-time costs, partially offset by favorable GLP-1 mix; recovery to 81.5% FY27E.
• EBITDA margin FY26E: 49.5% → 46.0% — Op margin compression of 400bp (44%→42% adj.) flowing through; R&D held at 14.8% (DKK 42B) to fund AMAZE Phase 3.
• EPS FY26E: $4.64 → $3.45 (-25.6%) — Margin compression + lower revenue base; consensus before update was ~$3.85 so we sit 10% below Street.
• Wegovy oral pill FY26E: DKK 9.5B (prior implicit) → DKK 11.5B (+21%) — Q1 DKK 2.26B annualizes to DKK 9B; we underwrite DKK 1B/Q lift from broader payer access H2'26.
• Wegovy injectable FY26E: DKK 76B (prior) → DKK 73B (-4%) — Some cannibalization by pill but HD (7.2mg) launches in 20 ex-US markets offset.
• Ozempic FY26E: DKK 124B (prior) → DKK 111B (-10.5%) — US -8 to -10% on price; IO offsets at +HSD vol; IRA MFP effective 2027-01 not yet in 2026 base.
• DCF inputs: WACC unchanged at 8.62%, terminal growth 2.5%, exit EV/EBITDA 10.5x (was 11.0x) — modest derating; risk-free held at 4.2%; beta 0.90 unchanged.
• Probability weighting (Bear 25 / Base 50 / Bull 25) — UNCHANGED. Wegovy pill validation strengthens bull case credibility (amycretin succession) but does not yet justify bull-weight increase pre-Phase 3 readout.
• DKK/USD assumption: 6.88 (current level) — sensitivity ~$1.00 per 1.0 DKK move; modest USD weakness vs initiation underpins ADR.
• Share count FY26E: 3,362M → 3,330M — DKK 20B buyback program at avg DKK 350 (~$51) retires ~57M shares; small effect on EPS but cumulative through FY27.
• Conviction 4 → 4 — Held; Wegovy pill upgrade offset by margin reset and lingering IRA 2027 unknowns.

Valuation Impact

Target Price Bridge: $61.50 → $60.00

Thesis Pillar Status — Post Q1

Competitive & Pipeline Watch — Next 12 Months

Bottom Line — What Changes & What Doesn't

WHAT CHANGES: (1) FY26E EPS cut 25.6% to $3.45 reflecting guidance midpoint (-8% revenue, -350bp EBITDA margin) plus continued US pricing pressure on Ozempic. (2) FY27E EPS cut 17% to $4.08 with partial margin recovery as Wegovy pill scales and MASH approval lifts mix. (3) TP $61.50 → $60.00 (-2.4%) — bridge is EBITDA cut (-$8.00) minus Wegovy pill terminal value uplift (+$3.50), buyback accretion (+$1.50) and time value (+$1.50). (4) Pillar 3 (pipeline) UPGRADED to conviction 4 from 3 — Phase 3 density confirmed. (5) NEW pillar: Wegovy pill launch trajectory tracked separately (conviction 5). WHAT DOESN'T: (1) Rating stays BUY — risk/reward +33% to TP despite stock +11% since initiation. (2) Overall conviction held at 4. (3) DCF macro inputs (WACC 8.62%, TG 2.5%) and probability weights (Bear 25 / Base 50 / Bull 25) unchanged. (4) Thesis architecture intact: franchise resilience + de-rating mean reversion + pipeline optionality. Upgrade trigger: amycretin Phase 2b ≥20% weight loss @64wks (Dec'26); MASH PDUFA approval (Nov'26); LLY retatrutide modest data. Downgrade trigger: LLY retatrutide >22% weight loss with manageable AE profile (key Dec'26 risk); IRA MFP discount >30% vs consensus; Wegovy pill weekly TRx falls below 150k by year-end.

Change Log

Disclaimer: This is not investment advice. Analysis is for educational/illustrative purposes. Past performance is not indicative of future results. Always do your own research.